164 related articles for article (PubMed ID: 31324478)
1. Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS.
Margalit O; Shacham-Shmueli E; Lawrence YR; Yang YX; Reiss KA; Golan T; Mamtani R; Halpern N; Aderka D; Giantonio B; Boursi B
Clin Colorectal Cancer; 2019 Sep; 18(3):e300-e307. PubMed ID: 31324478
[TBL] [Abstract][Full Text] [Related]
2. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
[TBL] [Abstract][Full Text] [Related]
3. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
5. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Yaeger R; Cowell E; Chou JF; Gewirtz AN; Borsu L; Vakiani E; Solit DB; Rosen N; Capanu M; Ladanyi M; Kemeny N
Cancer; 2015 Apr; 121(8):1195-203. PubMed ID: 25491172
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study.
Chibaudel B; André T; Tournigand C; Louvet C; Benetkiewicz M; Larsen AK; de Gramont A
Clin Colorectal Cancer; 2020 Sep; 19(3):200-208.e1. PubMed ID: 32303437
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
8. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
[TBL] [Abstract][Full Text] [Related]
9. Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.
Connell LC; Boucher TM; Chou JF; Capanu M; Maldonado S; Kemeny NE
J Surg Oncol; 2017 Mar; 115(4):480-487. PubMed ID: 28008623
[TBL] [Abstract][Full Text] [Related]
10. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
11. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
Sawada K; Nakamura Y; Yamanaka T; Kuboki Y; Yamaguchi D; Yuki S; Yoshino T; Komatsu Y; Sakamoto N; Okamoto W; Fujii S
Clin Colorectal Cancer; 2018 Sep; 17(3):198-205. PubMed ID: 29866615
[TBL] [Abstract][Full Text] [Related]
13. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
14. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
Yarom N; Gresham G; Boame N; Jonker D
Clin Colorectal Cancer; 2019 Dec; 18(4):e309-e315. PubMed ID: 31547963
[TBL] [Abstract][Full Text] [Related]
15. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Tozkir H; Albayrak D; Uzunoglu S; Cicin I
Hepatogastroenterology; 2015 Jun; 62(140):876-9. PubMed ID: 26902020
[TBL] [Abstract][Full Text] [Related]
16. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status.
Zihui Yong Z; Ching GTH; Ching MTC
J Surg Res; 2020 Feb; 246():325-334. PubMed ID: 30737098
[TBL] [Abstract][Full Text] [Related]
18. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
19. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.
Michl M; Taverna F; Kumbrink J; Schiergens TS; Heinemann V; Engel J; Kirchner T; Neumann J
Virchows Arch; 2021 Apr; 478(4):695-705. PubMed ID: 33300106
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for brain metastases in patients with metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Høgdall E; Poulsen TS; Pfeiffer P; Jensen BV; Yilmaz MK; Christensen IJ; Nielsen D
Acta Oncol; 2017 May; 56(5):639-645. PubMed ID: 28447565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
